Genmab (GMAB) Stock Analysis

November 11, 2026

This is a peer-relative look at Genmab (GMAB): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Genmab (GMAB) trades as an ADR rather than ordinary local shares — read it with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile fields for Genmab (GMAB)
Profile Item	GMAB
Name	Genmab A/S American Depositary Shares
Country/Region	Denmark
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology
GICS Sub-Industry	Biotechnology
Market Capitalization	32.98 billion USD
Currency	USD
Exchange	Nasdaq
Listing Date	June 1, 2009
Security Type	ADR

Price Performance

Cumulative Growth

GMAB

GSPC

Genmab (GMAB) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Genmab (GMAB) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Genmab (GMAB) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Genmab (GMAB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GMAB	Industry group median
Total Return (1Y)	91.17%	24.62%
Total Return (3Y, Annualized)	20.70%	20.37%
Total Return (5Y, Annualized)	3.98%	-4.02%

Risk Profile

Drawdown History

GMAB

GSPC

Genmab (GMAB) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Genmab (GMAB) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Genmab (GMAB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GMAB	Industry group median
Volatility (1Y, Annualized)	45.68%	66.36%
Beta (5Y)	0.72	0.93
Max Drawdown (5Y)	-61.79%	-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. GMAB is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Genmab (GMAB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GMAB	Industry group median
Sharpe Ratio (1Y)	1.90	0.36
Sortino Ratio (1Y)	3.82	0.58

Profitability

ROE (TTM)

Genmab (GMAB) posts ROE of 12.07%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.07%

Group distribution

Max: 109.18%
GMAB: 12.07%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Largest peers

LLY: 86.02%
NVS: 24.33%
AZN: 22.57%
JNJ: 20.02%
GMAB: 12.07%
MRK: 5.06%
ABBV: --

Where Genmab (GMAB) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Genmab (GMAB) keeps 16.97% of revenue as net profit, putting net margin in the upper peer quartile. After operating costs, interest, and taxes, more of each sales dollar reaches shareholders than it does at most industry peers.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.97%

Group distribution

Max: 18.05%
GMAB: 16.97%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Largest peers

LLY: 31.90%
AZN: 17.68%
NVS: 17.49%
GMAB: 16.97%
JNJ: 16.20%
ABBV: 15.67%
MRK: 3.64%

Where Genmab (GMAB) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Genmab (GMAB) turns 37.15% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.15%

Group distribution

Max: 83.12%
GMAB: 37.15%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Largest peers

LLY: 53.66%
ABBV: 39.59%
GMAB: 37.15%
MRK: 35.22%
NVS: 34.27%
AZN: 29.57%
JNJ: 25.74%

Where Genmab (GMAB) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Genmab (GMAB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GMAB	Industry group median
ROE (TTM)	12.07%	-26.66%
ROA (TTM)	8.24%	-12.50%
Net Margin (TTM)	16.97%	0.00%
Operating Margin (TTM)	37.15%	0.00%
Gross Margin (TTM)	92.67%	37.87%

Growth

Revenue Growth

Genmab (GMAB) grew revenue 19.19%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

Genmab (GMAB): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

Genmab (GMAB) grew earnings per share -9.23%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.

Genmab (GMAB): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

Genmab (GMAB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GMAB	Industry group median
Revenue Growth (YoY)	19.19%	11.45%
Revenue Growth (3Y CAGR)	21.23%	9.94%
EPS Growth (YoY)	-9.23%	4.28%
EPS Growth (3Y CAGR)	8.48%	4.17%

Financial Strength

Current Ratio (MRQ)

Genmab (GMAB) has current ratio of 2.45, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.45

Group distribution

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
GMAB: 2.45
Min: 0.10

Largest peers

GMAB: 2.45
LLY: 1.39
MRK: 1.35
JNJ: 1.02
AZN: 1.01
NVS: 0.88
ABBV: 0.87

Where Genmab (GMAB) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Genmab (GMAB) has debt-to-equity ratio of 0.82, in the higher-leverage quartile for its industry. The heavier reliance on borrowing can make earnings, rates, or refinancing conditions matter more.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.82

Group distribution

Max: 1.42
GMAB: 0.82
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Largest peers

NVS: 1.29
LLY: 1.23
MRK: 1.20
GMAB: 0.82
AZN: 0.66
JNJ: 0.55
ABBV: --

Where Genmab (GMAB) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Genmab (GMAB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GMAB	Industry group median
Current Ratio (MRQ)	2.45	5.52
Debt / Equity (MRQ)	0.82	0.15
Net Debt / EBITDA	2.45	1.08

Dividends

Dividend Yield (TTM)

Genmab (GMAB) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

GMAB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.88%
ABBV: 2.40%
MRK: 2.29%
JNJ: 1.94%
AZN: 1.73%
LLY: 0.49%
GMAB: 0.00%

Where Genmab (GMAB) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Genmab (GMAB) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

GMAB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 343.43%
ABBV: 117.35%
NVS: 90.46%
JNJ: 80.12%
AZN: 45.38%
LLY: 21.71%
GMAB: 0.00%

Where Genmab (GMAB) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Genmab (GMAB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GMAB	Industry group median
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Genmab (GMAB) trades at P/E ratio of 45.84, in the richer earnings-multiple quartile for its industry. That premium needs support from growth, durable earnings, or stronger business quality.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.84

Group distribution

Max: 85.34
GMAB: 45.84
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Largest peers

MRK: 148.21
ABBV: 50.05
GMAB: 45.84
LLY: 43.95
JNJ: 41.92
NVS: 31.02
AZN: 26.37

Where Genmab (GMAB) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Genmab (GMAB) trades at 7.68 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.68

Group distribution

Max: 58.18
Q3: 25.77
GMAB: 7.68
Median: 7.30
Q1: 3.01
Min: 0.01

Largest peers

LLY: 13.95
ABBV: 7.80
GMAB: 7.68
JNJ: 6.69
MRK: 5.37
NVS: 5.35
AZN: 4.63

Where Genmab (GMAB) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Genmab (GMAB) trades at 5.36 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.36

Group distribution

Max: 13.53
Q3: 6.54
GMAB: 5.36
Median: 3.25
Q1: 1.69
Min: -5.59

Largest peers

LLY: 29.96
NVS: 8.25
JNJ: 8.16
MRK: 8.06
AZN: 5.59
GMAB: 5.36
ABBV: -112.34

Where Genmab (GMAB) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Genmab (GMAB) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GMAB	Industry group median
P/E Ratio (TTM)	45.84	26.69
P/S Ratio (TTM)	7.68	7.30
P/B Ratio (MRQ)	5.36	3.25
Free Cash Flow Yield (TTM)	2.59%	-1.66%